# Aldosterone Blockade: Benefit Depends on the Setting

Potential long-term benefit must be weighed against hyperkalemia and other adverse effects. Monitoring is part of treatment, not an optional extra.

![Infographic: Aldosterone Blockade: Benefit Depends on the Setting](https://urinenephrology.org/visual-reference/images/mastery-aldosterone.png?v=20261003c)

## Receptor-mediated effects

Mineralocorticoid receptor activation contributes to sodium retention, inflammation, and fibrosis. Blocking this pathway has different evidence across cardiac and kidney populations.

## Identify the indication

Heart failure phenotype, resistant hypertension, albuminuric diabetic CKD, and potassium risk determine whether a particular agent is appropriate.

## Choose the agent for the studied indication

Spironolactone or eplerenone for appropriate heart-failure or resistant-hypertension indications is a different decision from finerenone for albuminuric diabetic CKD. Review potassium, kidney function, other RAAS drugs, NSAIDs, and supplements before starting; do not substitute agents solely because all block the same receptor.

## Plan surveillance before prescribing

For finerenone, measure potassium and kidney function before initiation and reassess potassium at about 4 weeks after starting or changing dose, then periodically. More frequent checks may be needed with illness or interacting drugs. Use the agent-specific eligibility and hold/restart rules.

## Interpret trial outcomes accurately

Separate albuminuria changes from hard kidney or cardiovascular outcomes. Confirm that a cited study tested the named drug in the relevant population.

## Balance protection and toxicity

Potential long-term benefit must be weighed against hyperkalemia and other adverse effects. Monitoring is part of treatment, not an optional extra.

## Supporting evidence

- [Supporting guideline or source](https://kdigo.org/wp-content/uploads/2022/10/KDIGO-2022-Clinical-Practice-Guideline-for-Diabetes-Management-in-CKD.pdf)

## Source lessons

- [aldosterone blockade](https://urinenephrology.org/mastery/cardiorenal/aldosterone-blockade.html)

Read alongside the full lessons; the findings and decisions shown here require the stated clinical context.